A study on vancomycin treatment, new data on the investigational Pfizer C diff vaccine, how individual antibiotics are ranked by risk for C difficile infection, and more.
MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence
C difficile, Antimicrobials, and the Patients Most Affected
Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort
New Meta-Analysis Highlights Most Effective Treatments for Clostridioides difficile Infection
Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile
LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients